Evidence map›Paper›PMID 28290094›Full record

ArticleMolecular diagnosis & therapy2017

Evaluating the Calling Performance of a Rare Disease NGS Panel for Single Nucleotide and Copy Number Variants.

P Cacheiro, A Ordóñez-Ugalde, B Quintáns, S Piñeiro-Hermida, J Amigo, M García-Murias, S I Pascual-Pascual, F Grandas, J Arpa, A Carracedo and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diagnosis & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

P CacheiroNeurogenetics Group, Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico de Santiago, level-2, Travesía da Choupana s/n, 15706, Santiago de Compostela, Spain.
A Ordóñez-UgaldeNeurogenetics Group, Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico de Santiago, level-2, Travesía da Choupana s/n, 15706, Santiago de Compostela, Spain.
B QuintánsNeurogenetics Group, Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico de Santiago, level-2, Travesía da Choupana s/n, 15706, Santiago de Compostela, Spain.
S Piñeiro-HermidaNeurogenetics Group, Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico de Santiago, level-2, Travesía da Choupana s/n, 15706, Santiago de Compostela, Spain.
J AmigoGrupo de Medicina Xenómica, CIBERER-U711, Santiago de Compostela, Spain.
M García-MuriasNeurogenetics Group, Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico de Santiago, level-2, Travesía da Choupana s/n, 15706, Santiago de Compostela, Spain.
S I Pascual-PascualServicio de Neuropediatría, Hospital Universitario La Paz, Madrid, Spain.
F GrandasUnidad de Trastornos del Movimiento, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Gregorio Marañón, Madrid, Spain.
J ArpaServicio de Neurología, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Madrid, Spain.
A CarracedoGrupo de Medicina Xenómica, CIBERER-U711, Santiago de Compostela, Spain.
M J SobridoNeurogenetics Group, Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico de Santiago, level-2, Travesía da Choupana s/n, 15706, Santiago de Compostela, Spain. ssobrido@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVariant detection protocols for clinical next-generation sequencing (NGS) need application-specific optimization. Our aim was to analyze the performance of single nucleotide variant (SNV) and copy number (CNV) detection programs on an NGS panel for a rare disease.

methodsThirty genes were sequenced in 83 patients with hereditary spastic paraplegia. The variant calls obtained with LifeScope, GATK UnifiedGenotyper and GATK HaplotypeCaller were compared with Sanger sequencing. The calling efficiency was evaluated for 187 (56 unique) SNVs and indels. Five multiexon deletions detected by multiple ligation probe assay were assessed from the NGS panel data with ExomeDepth, panelcn.MOPS and CNVPanelizer software.

resultsThere were 48/51 (94%) SNVs and 1/5 (20%) indels consistently detected by all the calling algorithms. Two SNVs were not detected by any of the callers because of a rare reference allele, and one SNV in a low coverage region was only detected by two algorithms. Regarding CNVs, ExomeDepth detected 5/5 multi-exon deletions, panelcn.MOPs 4/5 and only 3/5 deletions were accurately detected by CNVPanelizer.

conclusionsThe calling efficiency of NGS algorithms for SNVs is influenced by variant type and coverage. NGS protocols need to account for the presence of rare variants in the reference sequence as well as for ambiguities in indel calling. CNV detection algorithms can be used to identify large deletions from NGS panel data for diagnostic applications; however, sensitivity depends on coverage, selection of the reference set and deletion size. We recommend the incorporation of several variant callers in the NGS pipeline to maximize variant detection efficiency.

Indexed as

DNA Copy Number VariationsPolymorphism, Single NucleotideHigh-Throughput Nucleotide SequencingHumansRare DiseasesSpastic Paraplegia, Hereditary

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.